BridgeMD
New treatment option for Ventilator Dependent
Official title Short Effects of SIMT and EM in Prolonged Mechanically Ventilated Patients
ClinicalTrials.gov ID: NCT06368089
What this study is testing
- What it's testing
- Using mechanical ventilation for more than 18 hours can affect respiratory muscle and postural muscle control, making it difficult to wean off the ventilator and reducing mobility. The aim of this study is to: 1.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 to 80
You may be able to join if
- Patients with respiratory diseases who have been on mechanical ventilation for more than 48 hours and are ready to be weaned off or undergoing...
- The PaO2/FiO2 ratio is ≥ 150-200, with FiO2 ≤ 0.4-0.5 and PEEP ≤ 5-8 cmH2O, and a pH \> 7.3 in blood plasma.
- The age range is between 40 and 80 years old.
- Patients exhibit good self-awareness and cooperation in training (Riker score of 4).
- They can understand and communicate in Thai
You likely can't join if
- Clinical instability (HR \> 120 beats/minute, RR \> 30 breaths/minute, SatO2 \ 140 mmHg or \< 90 mmHg)
- Patients who can be extubated and use non-invasive ventilation only or successfully extubated within the first 24 hours.
- Patients with altered mental status (Glasgow Coma Score \ 4)
- Patients with limitations or contraindications such as inability to adjust the bed to a 45-degree angle or sit on the side of the bed, such as those...
- History of hemoptysis, pneumothorax
- History of neuromuscular diseases causing muscle weakness and decreased sensation.
See the full eligibility criteria
- Patients with respiratory diseases who have been on mechanical ventilation for more than 48 hours and are ready to be weaned off or undergoing weaning trials with continuous positive airway pressure (CPAP) or...
- The PaO2/FiO2 ratio is ≥ 150-200, with FiO2 ≤ 0.4-0.5 and PEEP ≤ 5-8 cmH2O, and a pH \> 7.3 in blood plasma.
- The age range is between 40 and 80 years old.
- Patients exhibit good self-awareness and cooperation in training (Riker score of 4).
- They can understand and communicate in Thai
- Clinical instability (HR \> 120 beats/minute, RR \> 30 breaths/minute, SatO2 \ 140 mmHg or \< 90 mmHg)
- Patients who can be extubated and use non-invasive ventilation only or successfully extubated within the first 24 hours.
- Patients with altered mental status (Glasgow Coma Score \ 4)
- Patients with limitations or contraindications such as inability to adjust the bed to a 45-degree angle or sit on the side of the bed, such as those with spinal cord injuries or recent head surgeries.
- History of hemoptysis, pneumothorax
- History of neuromuscular diseases causing muscle weakness and decreased sensation.
- Patients with excessive cardiac stimulation (\> 5 micrograms per kilogram per minute)
- Heart rate \> 140 beats per minute
- Hemoglobin levels \< 8-10 grams per deciliter
- Patients with difficult airway issues.
The study team makes the final eligibility decision.
Where it's taking place
- Songkhla, Thailand
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Songkhla, Thailand. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.